title: Antibody to capsular polysaccharides of Streptococcus pneumoniae: prevalence, persistence, and response to revaccination.
abstract: The prevalence of immunity to Streptococcus pneumoniae in the adult population of the United States is unknown. In the study described herein, military recruits had anticapsular IgG antibody to only 15% of common pneumococcal serotypes, whereas working men and elderly men had IgG antibody to 33% and 34% of the common serotypes, respectively (P < .001). Among eight elderly subjects, the prevalence of IgG antibody to capsular polysaccharides increased from 30% to 78% after pneumococcal vaccination; 6 years thereafter, the rate of positive reactions had declined to 58% and IgG levels had declined substantially. With revaccination, IgG levels returned to within (+/-) 40% of the original postvaccination levels. IgM and IgG antibody appeared or began to increase in titer 6 days after vaccination; the rate and degree of response were the same after the first and second exposures. Since most individuals rapidly develop IgG antibody after colonization by S. pneumoniae and since IgG confers immunity, these data suggest that pneumonia is infrequent among healthy adults not because preexisting immunity is widespread but because--with colonization--an immune response develops rapidly, preceding specific events that might lead to infection. Our findings support recommended vaccination procedures and suggest that wider application in subsets of healthy younger adults should be considered.
authors.affiliation: Infectious Disease Section, Veterans Affairs Medical Center, Houston, Texas 77030.
authors.forename: D M
authors.initials: DM
authors.lastname: Musher
authors.forename: J E
authors.initials: JE
authors.lastname: Groover
authors.forename: J M
authors.initials: JM
authors.lastname: Rowland
authors.forename: D A
authors.initials: DA
authors.lastname: Watson
authors.forename: J B
authors.initials: JB
authors.lastname: Struewing
authors.forename: R E
authors.initials: RE
authors.lastname: Baughn
authors.forename: M A
authors.initials: MA
authors.lastname: Mufson
mesh_terms: D000293:Adolescent; D000328:Adult; D000367:Age Factors; D000368:Aged; D000369:Aged, 80 and over; D000907:Antibodies, Bacterial / Q000097:blood*; D001428:Bacterial Vaccines / Q000494:pharmacology; D006801:Humans; D007117:Immunization, Secondary; D007074:Immunoglobulin G / Q000097:blood; D007075:Immunoglobulin M / Q000097:blood; D008297:Male; D008875:Middle Aged; D011008:Pneumococcal Infections / Q000453:epidemiology / Q000276:immunology / Q000517:prevention & control*; D011135:Polysaccharides, Bacterial / Q000276:immunology*; D016036:Seroepidemiologic Studies; D013296:Streptococcus pneumoniae / Q000276:immunology*; D014481:United States / Q000453:epidemiology
chemical_list: D000907:Antibodies, Bacterial; D001428:Bacterial Vaccines; D007074:Immunoglobulin G; D007075:Immunoglobulin M; D011135:Polysaccharides, Bacterial